Showing 1 - 10 of 15
world-wide rates of return, international capital flows and the distribution of wealth and welfare in the OECD. We find that …
Persistent link: https://www.econbiz.de/10010986497
world-wide rates of return, international capital flows and the distribution of wealth and welfare in the OECD. We find that …
Persistent link: https://www.econbiz.de/10005088817
In this paper we first document inequality trends in wages, hours worked, earnings, consumption, and wealth for Germany from the last twenty years. We generally find that inequality was relatively stable in West Germany until the German unification (which happened politically in 1990 and in our...
Persistent link: https://www.econbiz.de/10005025631
world-wide rates of return, international capital flows and the distribution of wealth and welfare in the OECD. We find that …
Persistent link: https://www.econbiz.de/10005666790
Demographic change has differential impacts on the welfare of current and future generations. In a simple closed economy, aging -- a relative scarcity of young workers -- increases wages, increasing the welfare of the young. At the same time, population aging will reduce rates of return to...
Persistent link: https://www.econbiz.de/10005778836
In this paper we first document inequality trends in wages, hours worked, earnings, consumption, and wealth for Germany from the last twenty years. We generally find that inequality was relatively stable in West Germany until the German Reunification, and then trended upwards for wages and...
Persistent link: https://www.econbiz.de/10008487512
Il presente rapporto analizza l'impatto del DL 15/04/2002 n. 63 del Governo Italiano ("Misure per il contenimento della spesa farmaceutica"), con particolare riferimento agli effetti indotti da tali misure sulle decisioni di investimento delle imprese, sulla struttura dell'industria di...
Persistent link: https://www.econbiz.de/10010791501
Il presente lavoro analizza i principali fatti caratterizzanti i comparti dei farmaci generici puri e dei branded off-patent in Italia, attraverso i dati relativi alle compravendite del 2002 (tramite il SSN e per via privata) di tutti i farmaci a base delle 10 molecole a brevetto scaduto che...
Persistent link: https://www.econbiz.de/10010861741
Dopo il rilascio dell'Autorizzazione all'Immissione in Commercio, un farmaco "H", prima di divenire concretamente disponibile in ospedale, deve completare una trafila che può differire da Regione a Regione, e addirittura, all'interno di una stessa Regione, da ASL ad ASL o da ospedale ad...
Persistent link: https://www.econbiz.de/10010929478
I farmaci innovativi ad alto costo ci fanno toccare con mano quali potranno essere i dilemmi della sanità futura se non si completano le riforme della governance di questo capitolo complesso della spesa pubblica (non solo federalismo, ma sistemi contabili e di reporting, schemi di...
Persistent link: https://www.econbiz.de/10010752623